ERS Genomics provides comment on issuance of University of California CRISPR/Cas9 patent including uses of CRISPR ‘in a cell’

Posted on by zymecom

U.S. Patent No. 10,227,611 issued to Dr. Emmanuelle Charpentier, University of California and University of Vienna

 DUBLIN, Ireland, 12 March 2019: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a new patent to Dr. Emmanuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively, UC). U.S. Patent No. 10,227,611 specifically includes uses of single guide RNA formats of the CRISPR/Cas9 technology ‘in a cell’. In a cell specifically includes any cell type, including animal, plant and human cells. ERS Genomics is an exclusive licensee of certain rights in the UC patents from Dr. Charpentier.

Eric Rhodes, CEO of ERS Genomics, said: “We are pleased that the seminal contribution of Dr. Charpentier and her colleagues to CRISPR/Cas9 technology continues to be recognized by patent offices in the United States and around the world.”

UC already has two granted patents relating to CRISPR/Cas9 in the U.S., with a fourth expected to grant soon.

For additional information please visit www.ersgenomics.com

 



This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.